137 related articles for article (PubMed ID: 15813839)
1. Controlled trial of interventions to increase testing and treatment for Helicobacter pylori and reduce medication use in patients with chronic acid-related symptoms.
Majumdar SR; Ross-Degnan D; Farraye FA; Lee M; Kemp JA; Lecates RF; Henning JM; Tunis SR; Schrammel P; Soumerai SB
Aliment Pharmacol Ther; 2005 Apr; 21(8):1029-39. PubMed ID: 15813839
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease.
Allison JE; Hurley LB; Hiatt RA; Levin TR; Ackerson LM; Lieu TA
Arch Intern Med; 2003 May; 163(10):1165-71. PubMed ID: 12767952
[TBL] [Abstract][Full Text] [Related]
3. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Murakami K; Okimoto T; Kodama M; Sato R; Miyajima H; Ono M; Inoue K; Watanabe K; Otsu S; Fujioka T
Helicobacter; 2006 Oct; 11(5):436-40. PubMed ID: 16961805
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial.
Jarbol DE; Kragstrup J; Stovring H; Havelund T; Schaffalitzky de Muckadell OB
Am J Gastroenterol; 2006 Jun; 101(6):1200-8. PubMed ID: 16771937
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic treatment and H. pylori eradication therapy for nonulcer dyspepsia.
Smucny J
Am Fam Physician; 2001 Nov; 64(9):1605-8. PubMed ID: 11730316
[No Abstract] [Full Text] [Related]
7. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for the management of dyspepsia.
Talley NJ; Vakil N;
Am J Gastroenterol; 2005 Oct; 100(10):2324-37. PubMed ID: 16181387
[TBL] [Abstract][Full Text] [Related]
9. Review article: Helicobacter pylori and gastro-oesophageal reflux disease.
Delaney B; McColl K
Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():32-40. PubMed ID: 16042657
[TBL] [Abstract][Full Text] [Related]
10. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
[TBL] [Abstract][Full Text] [Related]
11. One-week versus two-week H2-receptor antagonist in combination with amoxicillin and tinidazole for eradication of Helicobacter pylori infection.
Hsu CC; Chen JJ; Hu TH; Lu SN; Changchien CS
Hepatogastroenterology; 2005; 52(65):1617-21. PubMed ID: 16201128
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors and Helicobacter pylori gastritis: friends or foes?
Kuipers EJ
Basic Clin Pharmacol Toxicol; 2006 Sep; 99(3):187-94. PubMed ID: 16930292
[TBL] [Abstract][Full Text] [Related]
13. Survey of dyspepsia management in community.
Luman W; Ng HS
Singapore Med J; 2001 Jan; 42(1):26-9. PubMed ID: 11361234
[TBL] [Abstract][Full Text] [Related]
14. Cost analysis of a provincial drug program to guide the treatment of upper gastrointestinal disorders.
Bursey F; Crowley M; Janes C; Turner CJ
CMAJ; 2000 Mar; 162(6):817-23. PubMed ID: 10750472
[TBL] [Abstract][Full Text] [Related]
15. Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors.
Raghunath AS; Hungin AP; Mason J; Jackson W
Aliment Pharmacol Ther; 2009 Feb; 29(4):431-9. PubMed ID: 19035981
[TBL] [Abstract][Full Text] [Related]
16. Prevention of the rehaemorrhage of bleeding peptic ulcers: effects of Helicobacter pylori eradication and acid suppression.
Kikkawa A; Iwakiri R; Ootani H; Ootani A; Fujise T; Sakata Y; Amemori S; Tsunada S; Sakata H; Koyama T; Fujimoto K
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():79-84. PubMed ID: 15943852
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States.
Ladabaum U; Fendrick AM; Glidden D; Scheiman JM
Am J Gastroenterol; 2002 Dec; 97(12):3007-14. PubMed ID: 12492183
[TBL] [Abstract][Full Text] [Related]
18. Current indications for acid suppressants in dyspepsia.
Bytzer P; Talley NJ
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):385-400. PubMed ID: 11403534
[TBL] [Abstract][Full Text] [Related]
19. Persistence and adherence to proton pump inhibitors in daily clinical practice.
Van Soest EM; Siersema PD; Dieleman JP; Sturkenboom MC; Kuipers EJ
Aliment Pharmacol Ther; 2006 Jul; 24(2):377-85. PubMed ID: 16842465
[TBL] [Abstract][Full Text] [Related]
20. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Güliter S; Keleş H; Ozkurt ZN; Cengiz DU; Kolukisa E
Turk J Gastroenterol; 2005 Mar; 16(1):29-33. PubMed ID: 16252185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
